524 related articles for article (PubMed ID: 25143023)
1. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
[TBL] [Abstract][Full Text] [Related]
2. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
4. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
[TBL] [Abstract][Full Text] [Related]
5. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
[TBL] [Abstract][Full Text] [Related]
8. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
9. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
11. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
[TBL] [Abstract][Full Text] [Related]
12. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
13. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
[TBL] [Abstract][Full Text] [Related]
14. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
18. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
20. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
